BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang L, Wang B, You H, Wu X, Zhou J, Ou X, Jia J. Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. Hepatol Int 2018;12:237-43. [PMID: 29700765 DOI: 10.1007/s12072-018-9864-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Chen X, Wang G. Platelets: A review of their function and effects in liver diseases. Liver Research 2020;4:129-35. [DOI: 10.1016/j.livres.2020.08.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Jiang H, Li Y, Sheng Q, Dou X. Relationship between Hepatitis B virus infection and platelet production and dysfunction. Platelets 2021;:1-7. [PMID: 34806523 DOI: 10.1080/09537104.2021.2002836] [Reference Citation Analysis]
3 Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1:448-459. [PMID: 32039397 DOI: 10.1016/j.jhepr.2019.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Yang YT, Wang LL, Yan LT, Zhang LT, Zhou W, Chen QF, Chen Y, Zheng SJ, Duan ZP, Li JF. Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross-sectional study. Exp Ther Med 2020;20:243-50. [PMID: 32550883 DOI: 10.3892/etm.2020.8703] [Reference Citation Analysis]
5 Ming Y, Xin G, Ji B, Ji C, Wei Z, Zhang B, Zhang J, Yu K, Zhang X, Li S, Li Y, Xing Z, Niu H, Huang W. Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation. J Pharmacol Sci 2020;144:43-51. [PMID: 32653340 DOI: 10.1016/j.jphs.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wu X, Zhou J, Sun Y, Ding H, Chen G, Xie W, Piao H, Xu X, Jiang W, Ma H, Ma A, Chen Y, Xu M, Cheng J, Xu Y, Meng T, Wang B, Chen S, Shi Y, Kong Y, Ou X, You H, Jia J. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. Hepatol Int 2021;15:82-92. [PMID: 33460002 DOI: 10.1007/s12072-020-10114-1] [Reference Citation Analysis]
7 Mussbacher M, Brunnthaler L, Panhuber A, Starlinger P, Assinger A. Till Death Do Us Part-The Multifaceted Role of Platelets in Liver Diseases. Int J Mol Sci 2021;22:3113. [PMID: 33803718 DOI: 10.3390/ijms22063113] [Reference Citation Analysis]
8 Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med 2020;63:188-97. [PMID: 32884438 DOI: 10.33160/yam.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Masuch A, Budde K, Kastenmüller G, Artati A, Adamski J, Völzke H, Nauck M, Pietzner M. Metabolic signature associated with parameters of the complete blood count in apparently healthy individuals. J Cell Mol Med 2019;23:5144-53. [PMID: 31215770 DOI: 10.1111/jcmm.14383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]